{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:37:59Z","timestamp":1793929079231,"version":"4.8.0"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["2015 Research Scholar Grant (to AJO)"],"award-info":[{"award-number":["2015 Research Scholar Grant (to AJO)"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","award":["HHSN261201000034C"],"award-info":[{"award-number":["HHSN261201000034C"]}],"id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001808","name":"Public Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Comparative data on immunochemotherapy regimens for Waldenstr\u00f6m macroglobulinaemia\/lymphoplasmacytic lymphoma (<jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LPL<\/jats:styled-content>) are lacking. We analysed overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>), risk of hospitalizations, transfusions and plasmapheresis in a population\u2010based cohort of patients \u226565\u00a0years old initiating <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LPL<\/jats:styled-content> therapy in 1999\u20132013. To minimize bias, we applied a propensity score\u2010based causal inference method. We conducted three analyses of: patients treated with or without rituximab, patients treated with rituximab monotherapy or with combination immunochemotherapy, and regimens based on classic purine analogues or alkylators. Among 1310 patients, 78\u00b75% received rituximab. Patients who received rituximab had significantly better <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> [hazard ratio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) 0\u00b762, 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 0\u00b755\u20130\u00b771] and lower risk of transfusions (risk difference \u22123\u00b73%, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> \u22126\u00b73 to \u22120\u00b73) than those who did not, without a significant difference in hospitalizations or plasmapheresis. We observed no significant difference in <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 0\u00b791, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0\u00b779\u20131\u00b704) between rituximab monotherapy and combination immunochemotherapy, but toxicity outcomes were lower with rituximab alone. Neither survival (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 1\u00b710, 95%<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0\u00b792\u20131\u00b732) nor toxicity outcomes differed significantly between regimens based on purine analogues or alkylators. The survival advantage strongly supports rituximab as part of upfront therapy for <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LPL<\/jats:styled-content>, whereas regimens with either purine analogues or alkylating agents result in similar outcomes.<\/jats:p>","DOI":"10.1111\/bjh.14828","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T10:46:45Z","timestamp":1499251605000},"page":"106-115","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparative outcomes of immunochemotherapy regimens in Waldenstr\u00f6m macroglobulinaemia"],"prefix":"10.1111","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"first","affiliation":[{"name":"Department of Medicine Brown University Warren Alpert Medical School Providence RI USA"},{"name":"Division of Hematology\u2010Oncology Rhode Island Hospital Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Center for Statistical Sciences Brown University Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roee","family":"Gutman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Center for Statistical Sciences Brown University Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Boston MA USA"},{"name":"Division of Hematologic Malignancies Dana Farber Cancer Institute Boston MA USA"},{"name":"Deprtment of Medicine Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m Macroglobulinemia Boston MA USA"},{"name":"Division of Hematologic Malignancies Dana Farber Cancer Institute Boston MA USA"},{"name":"Deprtment of Medicine Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.725"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.261"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt298"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13264"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2012.12.005"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v071.i09"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.039"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9926"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30632-5"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.02.014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742411"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228029600500402"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24557"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20658"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5627"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.911869"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0814"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3447-8"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139025751"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647420"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00256-0"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2640"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7920"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711234"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.936013"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0126"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12760"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-553974"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh403"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi022"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566273"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6414"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200208001-00002"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14828","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:28:01Z","timestamp":1696296481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/bjh.14828"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14828","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]},"assertion":[{"value":"2017-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}